LIMN Liminatus Pharma, Inc.

Nasdaq liminatuspharma.com


$ 1.36 $ -0.02 (-1.42 %)    

Friday, 31-Oct-2025 19:15:19 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 1.39
$ 1.45
$ 1.31 x 195
$ 1.44 x 17
$ 1.35 - $ 1.45
$ 1.11 - $ 33.66
230,642
na
32.39M
$ -1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-04-2025 06-30-2025 10-Q
2 05-31-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-bl...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION